




PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/073,065
				Filing Date	February 12, 2002
				First Named Inventor	Shyam S. Mohapatra
				Group Art Unit	1648
				Examiner Name	Zachariah Lucas H/11
				Attorney Docket Number	USF-T156X
Sheet	1	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. '	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial; symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	R1	BEHERA, A. et al. "Adenovirus-mediated interferon γ gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling" <i>Human Gene Therapy</i> , 2002, 13:1697-1709.		
	R2	DOOLAN, D. et al. "Utilization of genomic sequence information to develop malaria vaccines" <i>J. Exp. Biol.</i> , 2003, 206:3789-3802.		
	R3	DUMONTEIL, E. et al. "DNA vaccines induce partial protection against <i>Leishmania mexicana</i> " <i>Vaccine</i> , 2003, 21:2161-2168.		
	R4	HELLERMANN, G. and MOHAPATRA, S. "Genetic therapy: on the brink of a new future" <i>Genetic Vaccines and Therapy</i> , 2003, 1:1-2.		
	R5	KUMAR, M. et al. "Chitosan IFN- γ -pDNA nanoparticle (CIN) therapy for allergic asthma" <i>Genetic Vaccines and Therapy</i> , 2003, 1:1-10.		
	R6	KUMAR, M.N.V.R. et al. "Cationic poly(lactide-co-glycolide) nanoparticles as efficient <i>in vivo</i> gene transfection agents" <i>J. Nanosci. Nanotech</i> , 2004, 4(8):1-5.		
	R7	KUMAR, M.N.V.R. et al. "Cationic silica nanoparticles as gene carriers: synthesis, characterization and transfection efficiency <i>in vitro</i> and <i>in vivo</i> " <i>J. Nanosci. Nanotech.</i> , 2004, 4(7):1-6.		
	R8	KUMAR, M.N.V.R. et al. "Nanoparticle-mediated gene delivery: state of the art" <i>Expert Opin. Biol. Ther.</i> , 2004, 4(8):1-12 (author's proof; pages 1213-1224 as published).		
	R9	KUMAR, M. et al. "Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection" <i>Human Gene Therapy</i> , 2002, 13:1415-1425.		
	R10	KUMAR, M. et al. "Intranasal IFN- γ gene transfer protects BALB/c mice against respiratory syncytial virus infection" <i>Vaccine</i> , 2000, 18:558-567.		
	R11	MATSUSE, H. et al. "Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness" <i>J. Immunology</i> , 2000, 164:6583-6592.		
	R12	MOHAPATRA, S. "Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus" <i>Pediatr. Infect. Dis. J.</i> , 2003, 22:S100-S104.		
	R13	MOORTHY, V. et al. "Malaria vaccine developments" <i>The Lancet</i> , 2004, 363:150-156.		


Examiner Signature		Date Considered	8/5/07
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, ~~you~~ are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/073,065
Filing Date	February 12, 2002
First Named Inventor	Shyam S. Mohapatra
Group Art Unit	1648
Examiner Name	Zachariah Lucas 4:11
Attorney Docket Number	USF-T156X

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	MUTHUMANI, K. et al. "Issues for improving multiplasmid DNA vaccines for HIV-1" Vaccine, 2002, 20:1999-2003.	
	R15	WARD, B.J. "Vaccine adverse events in the new millennium: is there reason for concern?" Bulletin of the World Health Organization, 2000, 78(2):205-215.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner
SignatureDate
Considered

8/5/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.